PYXS Stock Overview
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Pyxis Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.30 |
| 52 Week High | US$6.85 |
| 52 Week Low | US$1.35 |
| Beta | 1.51 |
| 1 Month Change | 12.27% |
| 3 Month Change | 8.86% |
| 1 Year Change | 51.94% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.42% |
Recent News & Updates
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Mar 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Jan 18Recent updates
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Mar 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Jan 18Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Feb 18
Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation
Sep 01Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06
Aug 15We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely
Apr 13Shareholder Returns
| PYXS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.1% | 0.4% | 1.0% |
| 1Y | 51.9% | 0.9% | 21.9% |
Return vs Industry: PYXS exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: PYXS exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| PYXS volatility | |
|---|---|
| PYXS Average Weekly Movement | 19.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PYXS's share price has been volatile over the past 3 months.
Volatility Over Time: PYXS's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 50 | Lara Sullivan | www.pyxisoncology.com |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy.
Pyxis Oncology, Inc. Fundamentals Summary
| PYXS fundamental statistics | |
|---|---|
| Market cap | US$249.97m |
| Earnings (TTM) | -US$73.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs PYXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYXS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$73.79m |
| Earnings | -US$73.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PYXS perform over the long term?
See historical performance and comparison